Hundreds of biotech executives sent a letter to FDA Director Marty Makary urging regulatory predictability and warning that volatility threatens U.S. innovation. Signatories cited recent agency actions and called for clearer, stable review standards to reduce development risk for sponsors. The move formalizes private-sector pressure on the agency as companies weigh investment and development timetables.